High Neutropenia Risk Chemotherapy
Showing 1 - 25 of >10,000
G-CSF Use in Breast Cancer, Lung Cancer, or Lymphoma Treated
Completed
- Breast Cancer
- Lung Cancer
- filgrastim, TBO-filgrastim or pegfilgrastim
- (no location specified)
Jul 24, 2021
Non Small Cell Lung Cancer Trial in China (Efgbemalenograstim alfa)
Not yet recruiting
- Non Small Cell Lung Cancer
- Efgbemalenograstim alfa
-
Zhengzhou, Henan, China
- +9 more
Nov 16, 2023
Febrile Neutropenia Trial (Early Discontinuation of Antibiotics, Standard of Care)
Not yet recruiting
- Febrile Neutropenia
- Early Discontinuation of Antibiotics
- Standard of Care
- (no location specified)
Mar 24, 2023
AMS Intervention for Early Adaptation of Empirical Antibiotic
Completed
- Neutropenia
-
Nice, FranceUniversity Hospital of Nice
Mar 29, 2023
Neutropenia, Febrile Trial (Comparison short vs extended EBAT treatment group)
Not yet recruiting
- Neutropenia, Febrile
- Comparison short vs extended EBAT treatment group
- (no location specified)
Jun 21, 2023
Drug/Agent Toxicity by Tissue/Organ, Leukemia, MDS Trial in Chicago, Kankakee (amifostine trihydrate, cytarabine, mitoxantrone
Withdrawn
- Drug/Agent Toxicity by Tissue/Organ
- +3 more
- amifostine trihydrate
- +2 more
-
Chicago, Illinois
- +3 more
Jan 31, 2023
High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation Trial in Shanghai
Recruiting
- High-risk Stage II Colorectal Cancer
- +2 more
- mFOLFIRINOX adjuvant chemotherapy
- mFOLFOX6/XELOX adjuvant chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 12, 2023
Radiotherapy, Immunotherapy, Liver Metastases Trial in Shanghai (SBRT, Chemotherapy, PD-1 antibody)
Recruiting
- Radiotherapy
- +3 more
- SBRT
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 2, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Haematopoietic Stem Cell Transplant, Autologous Trial in Melbourne,
Completed
- Acute Myeloid Leukemia
- +4 more
- FDG-PET/CT
- Conventional CT
-
Melbourne, Victoria, Australia
- +1 more
May 15, 2022
Febrile Neutropenia Trial in Melbourne (Piperacillin and Tazobactam for Injection, Cefepime Injection, Ceftazidime Injection)
Recruiting
- Febrile Neutropenia
- Piperacillin and Tazobactam for Injection
- +5 more
-
Melbourne, Victoria, AustraliaRoyal Children's Hospital
Nov 23, 2021
Cervical Cancer, Induction Chemo, Immunotherapy Trial in Tianjin (Toripalimab)
Recruiting
- Cervical Cancer
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Oct 16, 2023
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Pegylated Liposomal Doxorubicin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 15, 2023
Nasopharyngeal Carcinoma, De-escalation Therapy Trial in Guangzhou (Cisplatin-based induction chemo, Full course of PD-1/PD-L1
Recruiting
- Nasopharyngeal Carcinoma
- De-escalation Therapy
- Cisplatin-based induction chemotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 16, 2023
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Peritoneal Metastases From Colorectal Cancer Trial in Milano (Pressurized intraperitoneal aerosol chemo (PIPAC))
Recruiting
- Peritoneal Metastases From Colorectal Cancer
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
-
Milano, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Oct 16, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)
Recruiting
- Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
May 24, 2023
Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia Trial in Germany, Italy, Spain
Completed
- Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
-
Aurich, Germany
- +59 more
Jun 6, 2022
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Induction chemo plus Concurrent chemo, Concurrent chemo, IMRT)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Induction chemotherapy plus Concurrent chemotherapy
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 17, 2022
Breast Cancer Trial in Gainesville (12-week Intervention Period, 12-week Observation Period)
Not yet recruiting
- Breast Cancer
- 12-week Intervention Period
- 12-week Observation Period
-
Gainesville, FloridaIntegrative Cardiovascular Physiology Laboratory, University of
Jun 13, 2023
Gastric Cancer Trial in Krakow (FLOT4 + HIPEC + Surgery, FLOT4 + Surgery)
Recruiting
- Gastric Cancer
- FLOT + HIPEC + Surgery
- FLOT + Surgery
-
Krakow, Lesser Poland Voivodship, PolandDepartment of General, Oncological, Gastroenterological Surgery
Nov 9, 2022
Solid Tumors, Brain Tumors Trial in Cincinnati (Amifostine)
Terminated
- Solid Tumors
- Brain Tumors
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Dec 29, 2021
Peritoneum Cancer, Peritoneal Carcinomatosis, Peritoneal Metastases Trial in Odense (PIPAC)
Recruiting
- Peritoneum Cancer
- +3 more
-
Odense, DenmarkOdense PIPAC Center, Department of Surgery, Odense University Ho
Oct 5, 2022
Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)
Recruiting
- Breast Cancer
- Patritumab deruxtecan
- +2 more
-
Barcelona, SpainHospital Clinic de Barcelona
Nov 28, 2022
Brain and CNS Tumors Trial in Australia, United States (Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy)
Active, not recruiting
- Brain and Central Nervous System Tumors
- Induction Chemotherapy
- +3 more
-
Palo Alto, California
- +5 more
Nov 29, 2022